Should You Buy RAPT Therapeutics Inc (RAPT) Today? Analysis, Price Targets, and 2026 Outlook.
Conclusion
Hold
Latest Price
57.630
1 Day change
-0.03%
52 Week Range
57.700
Analysis Updated At
2026/01/26
RAPT Therapeutics Inc is not a good buy for a long-term beginner investor at this time. The stock is being acquired by GSK for $58 per share, which caps its upside potential. The pre-market price of $57.69 is already near the acquisition price, leaving minimal room for growth. Additionally, the company's financial performance is weak, and analysts have downgraded the stock due to the acquisition. For a long-term investment strategy, this stock does not align with the user's goals.
Technical Analysis
The stock is in an overbought condition with an RSI of 89.26, indicating limited upside potential. The MACD is positive and expanding, but the acquisition deal caps further price movement. The current pre-market price of $57.69 is close to the resistance level of $58 (acquisition price).
Options Data
Bullish
Open Interest Put-Call Ratio
Bearish
Option Volume Put-Call Ratio
Technical Summary
Sell
4
Buy
9
Positive Catalysts
The acquisition by GSK offers a 65% premium over the previous closing price, providing a stable exit point for current shareholders.
Neutral/Negative Catalysts
The acquisition caps the stock's upside at $58, leaving minimal growth potential. Investigations into the fairness of the acquisition process may create uncertainty. Hedge funds are selling, and the company's financial performance is weak.
Financial Performance
In Q3 2025, revenue remained stagnant at $0, net income dropped by -4.62% YoY to -$17.58 million, and EPS fell by -82.85% YoY to -0.65. The company is not showing signs of financial growth.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
All analysts have downgraded the stock to neutral or hold ratings with a price target of $58 due to the acquisition by GSK. Previously, the stock had bullish ratings, but the acquisition has shifted sentiment.
Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 67.78 USD with a low forecast of 56 USD and a high forecast of 95 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast RAPT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RAPT is 67.78 USD with a low forecast of 56 USD and a high forecast of 95 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 57.650
Low
56
Averages
67.78
High
95
Current: 57.650
Low
56
Averages
67.78
High
95
Barclays
Overweight -> Equal Weight
downgrade
$58
AI Analysis
2026-01-21
Reason
Barclays
Price Target
$58
AI Analysis
2026-01-21
downgrade
Overweight -> Equal Weight
Reason
Barclays downgraded Rapt Therapeutics to Equal Weight from Overweight with a $58 price target after GSK entered into an agreement to acquire all the outstanding shares of Rapt for $58 per share in cash.
Leerink
Thomas Smith
Outperform -> Market Perform
downgrade
$58
2026-01-21
Reason
Leerink
Thomas Smith
Price Target
$58
2026-01-21
downgrade
Outperform -> Market Perform
Reason
Leerink analyst Thomas Smith downgraded Rapt Therapeutics to Market Perform from Outperform with a $58 price target after GSK entered into an agreement to acquire all the outstanding shares of Rapt for $58 per share in cash
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for RAPT
